NY-ESO-1 is a "cancer-testis" antigen expressed in epithelial ovarian cancer (EOC) and is among the most immunogenic tumor antigens defined to date. The NY-ESO-1 peptide epitope, ESO(157-170), is recognized by HLA-DP4-restricted CD4+ T cells and HLA-A2- and A24-restricted CD8+ T cells. To test whether providing cognate helper CD4+ T cells would enhance the antitumor immune response, we conducte...

34 Pfs25 is a leading candidate for a malaria transmission blocking vaccine who’s potential has 35 been demonstrated in a Phase 1 trial with recombinant Pfs25 formulated with Montanide 36 ISA51. Because of limited sequence polymorphism, the anti-Pfs25 antibodies induced by this 37 vaccine are likely to have transmission blocking or reducing activity against most, if not all, field 38 isolates. ...

In the present study formaldehyde inactivated Montanide ISA70 based MG vaccine from the PCR confirmed positive local isolate was prepared and evaluated in broilers. An amount of immune gen per 0.3ml of the dose was 10 7 Colony forming units of the bacteria. At the age of 14 days, the broilers were randomly divided into three groups (A, B and C), each having twenty birds. Each bird of group A, B...

Twelve peptides derived from melanocyte differentiation proteins and cancer-testis Ags were combined and administered in a single mixture to patients with resected stage IIB, III, or IV melanoma. Five of the 12 peptides included in this mixture had not previously been evaluated for their immunogenicity in vivo following vaccination. We report in this study that at least three of these five pept...

A 74-year-old woman who had undergone right nephrectomy due to renal cell carcinoma (RCC) was found to have developed multiple lung metastasis of RCC 5 years after surgery. The patient was treated with interferon-a, but she was unable to tolerate this therapy because of fever and severe malaise. At this time, as molecular-targeted therapy, such as the multikinase inhibitor sorafenib, was not av...

This study aimed to determine the effectiveness of a pregnant mare immunization of a Rhodococcus equi (R. equi) vaccine candidate containing a water-based nanoparticle mineral oil adjuvanted (Montanide IMS 3012) inactive bacterin and virulence-associated protein A (VapA), as well as the administration of anti-R. equi hyperimmune (HI) plasma against R. equi challenge in the mares' foals. The eff...

Correlation of hepatitis C virus (HCV) spontaneous resolution with Th1 and CD8(+)CTL responses during natural infection implies the potentiality of poly-CTL-epitopic HCV vaccines. We recently reported in silico design and construction of DNA vaccines (pcPOL-plasmids) harboring HCV CTL epitopes. Herein, we provide data of mice immunization by pcPOL, (encoding; core(132-142) [C], E2(405-414) [E(4...

In vitro culture of live adult worms were made in RPMI 1640 medium at a concentration of approximately 50 worms / ml in a 0 culture flask at 37 C for 24 hours and the culture supernatant was used as antigen. The E/S antigen was purified by thiol – sepharose affinity chromatography. On western blot analysis, it was demonstrated that the crude E/S antigen showed five reactive bands at 24, 29, 46,...

Cell division associated 1 (CDCA1) was screened as an oncogene that is overexpressed on several cancers, including prostate cancer. A highly immunogenic HLA-A*2402-restricted epitope peptide corresponding to part of the CDCA1 protein was also identified. A phase I clinical trial was conducted for patients with castration resistant prostate cancer (CRPC) using a CDCA1 peptide vaccination. Twelve...

Despite the tremendous potential of peptide-based cancer vaccines, their efficacy has been limited in humans. Recent innovations in tumour exome sequencing have signalled the new era of personalized immunotherapy with patient-specific neoantigens, but a general methodology for stimulating strong CD8α+ cytotoxic T-lymphocyte (CTL) responses remains lacking. Here we demonstrate that high-density ...